[go: up one dir, main page]

MX2022013744A - Bloqueadores del canal de proteína e e inhibidores de marco de lectura abierto 3a (orf3) como agentes anticovid-19. - Google Patents

Bloqueadores del canal de proteína e e inhibidores de marco de lectura abierto 3a (orf3) como agentes anticovid-19.

Info

Publication number
MX2022013744A
MX2022013744A MX2022013744A MX2022013744A MX2022013744A MX 2022013744 A MX2022013744 A MX 2022013744A MX 2022013744 A MX2022013744 A MX 2022013744A MX 2022013744 A MX2022013744 A MX 2022013744A MX 2022013744 A MX2022013744 A MX 2022013744A
Authority
MX
Mexico
Prior art keywords
orf3
inhibitors
protein channel
covid
agents
Prior art date
Application number
MX2022013744A
Other languages
English (en)
Inventor
Isaiah Arkin
Tomar Prabhat Pratap Singh
Miriam Krugliak
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of MX2022013744A publication Critical patent/MX2022013744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones farmacéuticas que comprenden un bloqueador del canal de proteína E de SARS-CoV-2 e inhibidores de ORF3 para tratar o prevenir la virulencia de SARS-CoV-2 en un sujeto. Se proporciona además una composición farmacéutica que comprende un bloqueador del canal de proteína E de SARS-CoV-2 o un inhibidor de ORF3 para prevenir la entrada de SARS-CoV-2 en las células, descapsidación y/o liberación de una célula.
MX2022013744A 2020-05-01 2021-05-02 Bloqueadores del canal de proteína e e inhibidores de marco de lectura abierto 3a (orf3) como agentes anticovid-19. MX2022013744A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018598P 2020-05-01 2020-05-01
US202063117619P 2020-11-24 2020-11-24
PCT/IL2021/050501 WO2021220284A1 (en) 2020-05-01 2021-05-02 E protein channel blockers and orf3 inhibitors as anti-covid-19 agents

Publications (1)

Publication Number Publication Date
MX2022013744A true MX2022013744A (es) 2023-01-24

Family

ID=76375375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013744A MX2022013744A (es) 2020-05-01 2021-05-02 Bloqueadores del canal de proteína e e inhibidores de marco de lectura abierto 3a (orf3) como agentes anticovid-19.

Country Status (10)

Country Link
EP (1) EP4142702A1 (es)
JP (1) JP2023524522A (es)
KR (1) KR20230035524A (es)
CN (1) CN115867265A (es)
AU (1) AU2021265602A1 (es)
BR (1) BR112022022243A2 (es)
CA (1) CA3177537A1 (es)
IL (1) IL297852A (es)
MX (1) MX2022013744A (es)
WO (1) WO2021220284A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117942341A (zh) * 2022-10-27 2024-04-30 北京化工大学 异喹啉类生物碱在预防和治疗冠状病毒中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094566A (en) 1963-12-28 1967-12-13 Zh Biseibutsu Kagaku Kenkyukai Kasugamycin and processes for the preparation thereof
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP0942752B1 (en) 1996-08-23 2005-04-20 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5919826A (en) 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
AU2002357379A1 (en) 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
RU2006136381A (ru) 2004-03-15 2008-04-27 Анормед, Инк. (Ca) Способ получения антагониста cxcr4
AU2011235981B2 (en) * 2004-09-20 2012-09-27 Mount Sinai School Of Medicine Use of Memantine (Namenda) to Treat Autism, Compulsivity, and Impulsivity
US8846607B2 (en) * 2004-10-29 2014-09-30 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
US20070196428A1 (en) 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
US8420665B2 (en) 2008-01-11 2013-04-16 Northwestern University Anti-cancer compounds
EP2691408B1 (en) 2011-03-31 2017-06-28 Celgene International SÁRL Synthesis of 5-azacytidine
WO2014125499A1 (en) 2013-02-13 2014-08-21 Natco Pharma Limited Improved and commercially viable process for the preparation of high pure plerixafor base
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
KR101897803B1 (ko) * 2017-11-17 2018-09-12 한국화학연구원 아르보바이러스 감염 저해제
IT201800001169A1 (it) * 2018-01-17 2019-07-17 Fond Per Listituto Oncologico Di Ricerca Ior Nuovi farmaci senolitici inibitori cxcr4
GB2613460B (en) * 2020-04-20 2025-07-23 Lloyd Hung Loi Tran Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a
EP3906922A1 (en) * 2020-05-07 2021-11-10 4Living Biotech New compositions and methods of treating covid-19 disease
US20230183323A1 (en) * 2020-05-19 2023-06-15 Brown University Methods for preventing, reversing or treating a covid-19 infection
CN111773282A (zh) * 2020-06-09 2020-10-16 广东金骏康生物技术有限公司 一种药食两用的中药制剂及其应用

Also Published As

Publication number Publication date
KR20230035524A (ko) 2023-03-14
CN115867265A (zh) 2023-03-28
CA3177537A1 (en) 2021-11-04
JP2023524522A (ja) 2023-06-12
BR112022022243A2 (pt) 2022-12-20
IL297852A (en) 2023-01-01
WO2021220284A1 (en) 2021-11-04
EP4142702A1 (en) 2023-03-08
AU2021265602A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
MX2025004604A (es) Nuevos compuestos triheterociclicos
SV2009003227A (es) Composiciones de inhibidores de chk 1 ref. x-17672
EA201000219A1 (ru) Способ и композиция для лечения в-клеточных пролиферативных нарушений
MX2023003443A (es) Inhibidores de la proteína cinasa alfa 1 y métodos de uso.
MX2009000506A (es) Composiciones y metodos para el tratamiento de la mucormicosis y otras enfermedades micoticas.
MX2022013744A (es) Bloqueadores del canal de proteína e e inhibidores de marco de lectura abierto 3a (orf3) como agentes anticovid-19.
ZA202402178B (en) 3clpro protease inhibitor
WO2022150610A3 (en) Sars-cov-2-specific t cell receptors and related materials and methods of use
MX2024000986A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus.
CR20250103A (es) Moduladores de la alfa-1 antitripsina
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2022204581A3 (en) Tgf-beta inhibitors and use thereof
MX2024004993A (es) Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2025003571A (es) Inhibidores de tead y metodos de uso de los mismos
MX2025003568A (es) Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap)
BR112022003768A2 (pt) Compostos inibidores de perk
AU2003267623A1 (en) An inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer
MX2023004854A (es) Composicion para tratar enfermedades vasculares, composicion para evitar enfermedades vasculares, composicion para tratar hipertension y composicion para evitar hipertension.
CR20240494A (es) Composiciones y métodos para inhibir la expresión de snca
CL2024003177A1 (es) Inhibidores de pi3ka.
MX2024002684A (es) Metodos para la prevencion y tratamiento de sinucleinopatias.
GB2459197A (en) Compositions and method for removing hair
MX2010006926A (es) 4-imidazolidinonas como inhibidores del canal de potasio kv1.5.
IL320497A (en) RNAI agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use